Avidity Partners Management LP Vaxcyte, Inc. Transaction History

Avidity Partners Management LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$59.79 - $81.05 $17.1 Million - $23.2 Million	-286,137 Reduced 50.19%	284,000 $19.4 Million
Q4 2023 Feb 14, 2024	SELL	$45.35 - $63.41 $8.44 Million - $11.8 Million	-186,028 Reduced 24.6%	570,137 $35.8 Million
Q3 2023 Nov 14, 2023	SELL	$46.0 - $53.1 $5.47 Million - $6.31 Million	-118,835 Reduced 13.58%	756,165 $38.5 Million
Q2 2023 Aug 14, 2023	BUY	$34.66 - $54.07 $12.7 Million - $19.7 Million	365,000 Added 71.57%	875,000 $43.7 Million
Q1 2023 May 15, 2023	SELL	$36.27 - $47.2 $40.1 Million - $52.2 Million	-1,105,400 Reduced 68.43%	510,000 $19.1 Million
Q4 2022 Feb 14, 2023	BUY	$20.58 - $47.95 $20.3 Million - $47.3 Million	986,700 Added 156.94%	1,615,400 $77.5 Million
Q3 2022 Nov 14, 2022	BUY	$21.69 - $28.53 $13.6 Million - $17.9 Million	628,700 New	628,700 $15.1 Million

352

122M

775K

433K

Ticker PCVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,315,100
Market Cap $5.1B
Description
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...

Get notified when there are updates to the investment portfolio of Avidity Partners Management LP, based on Form 13F filings with the SEC.

Stay updated on Avidity Partners Management LP with notifications on news.